Literature DB >> 21765218

3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.

Noam Levaot1, Paul D Simoncic, Ioannis D Dimitriou, Andrew Scotter, Jose La Rose, Adeline H M Ng, Thomas L Willett, Chiachien J Wang, Salima Janmohamed, Marc Grynpas, Ernst Reichenberger, Robert Rottapel.   

Abstract

A fine balance between bone resorption by osteoclasts and bone formation by osteoblasts maintains bone homeostasis. In patients with cherubism, gain-of-function mutations in 3BP2, which is encoded by SH3-domain binding protein 2 (SH3BP2), cause cystic lesions with activated osteoclasts that lead to craniofacial abnormalities. However, little is known about the function of wild-type 3BP2 in regulating bone homeostasis. Here we have shown that 3BP2 is required for the normal function of both osteoblasts and osteoclasts. Initial analysis showed that Sh3bp2-/-mice developed osteoporosis as a result of reduced bone formation despite the fact that bone resorption was impaired. We demonstrated using reciprocal bone marrow chimeras, a cell-intrinsic defect of the osteoblast and osteoclast compartments in vivo. Further, Sh3bp2-/- osteoblasts failed to mature and form mineralized nodules in vitro, while Sh3bp2-/- osteoclasts spread poorly and were unable to effectively degrade dentine matrix in vitro. Finally, we showed that 3BP2 was required for Abl activation in osteoblasts and Src activation in osteoclasts, and demonstrated that the in vitro defect of each cell type was restored by the respective expression of activated forms of these kinases. These findings reveal an unanticipated role for the 3BP2 adapter protein in osteoblast function and in coordinating bone homeostatic signals in both osteoclast and osteoblast lineages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21765218      PMCID: PMC3148735          DOI: 10.1172/JCI45843

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK.

Authors:  D Barilá; R Mangano; S Gonfloni; J Kretzschmar; M Moro; D Bohmann; G Superti-Furga
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

2.  DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk.

Authors:  Wei Zou; Jennifer L Reeve; Yuli Liu; Steven L Teitelbaum; F Patrick Ross
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

3.  Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.

Authors:  Xiangwei Wu; Lijuan Pang; Weiqi Lei; William Lu; Jun Li; Zhaoyang Li; Frank J Frassica; Xueling Chen; Mei Wan; Xu Cao
Journal:  Cell Stem Cell       Date:  2010-11-05       Impact factor: 24.633

4.  3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.

Authors:  Amel GuezGuez; Virginie Prod'homme; Xavier Mouska; Alice Baudot; Claudine Blin-Wakkach; Robert Rottapel; Marcel Deckert
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

5.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  SLP-76 couples Syk to the osteoclast cytoskeleton.

Authors:  Jennifer L Reeve; Wei Zou; Yuli Liu; Jonathan S Maltzman; F Patrick Ross; Steven L Teitelbaum
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

7.  Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT.

Authors:  Upasana Shukla; Tomoko Hatani; Kenji Nakashima; Kazuhiro Ogi; Kiyonao Sada
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

8.  Long-term imatinib therapy promotes bone formation in CML patients.

Authors:  Stephen Fitter; Andrea L Dewar; Panagiota Kostakis; L Bik To; Timothy P Hughes; Marion M Roberts; Kevin Lynch; Barrie Vernon-Roberts; Andrew C W Zannettino
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

9.  Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Authors:  I Nakamura; M F Pilkington; P T Lakkakorpi; L Lipfert; S M Sims; S J Dixon; G A Rodan; L T Duong
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

10.  DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells.

Authors:  Mitsuru Yagi; Takeshi Miyamoto; Yumi Sawatani; Katsuya Iwamoto; Naobumi Hosogane; Nobuyuki Fujita; Kozo Morita; Ken Ninomiya; Toru Suzuki; Kana Miyamoto; Yuichi Oike; Motohiro Takeya; Yoshiaki Toyama; Toshio Suda
Journal:  J Exp Med       Date:  2005-08-01       Impact factor: 14.307

View more
  33 in total

1.  Investigating global gene expression changes in a murine model of cherubism.

Authors:  Tulika Sharma; Justin Cotney; Vijender Singh; Archana Sanjay; Ernst J Reichenberger; Yasuyoshi Ueki; Peter Maye
Journal:  Bone       Date:  2020-03-10       Impact factor: 4.398

2.  Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2.

Authors:  Yoshinori Matsumoto; Jose La Rose; Oliver A Kent; Melany J Wagner; Masahiro Narimatsu; Aaron D Levy; Mitchell H Omar; Jiefei Tong; Jonathan R Krieger; Emily Riggs; Yaryna Storozhuk; Julia Pasquale; Manuela Ventura; Behzad Yeganeh; Martin Post; Michael F Moran; Marc D Grynpas; Jeffrey L Wrana; Giulio Superti-Furga; Anthony J Koleske; Ann Marie Pendergast; Robert Rottapel
Journal:  J Clin Invest       Date:  2016-10-31       Impact factor: 14.808

Review 3.  SH3 domains: modules of protein-protein interactions.

Authors:  Natalya Kurochkina; Udayan Guha
Journal:  Biophys Rev       Date:  2012-06-20

4.  RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146.

Authors:  Yoshinori Matsumoto; Jose Larose; Oliver A Kent; Melissa Lim; Adele Changoor; Lucia Zhang; Yaryna Storozhuk; Xiaohong Mao; Marc D Grynpas; Feng Cong; Robert Rottapel
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

5.  Cloning and characterization of the human SH3BP2 promoter.

Authors:  Chun Fan; Robert J Gaivin; Thomas A Marth; Belinda Willard; Michael A Levine; Steven A Lietman
Journal:  Biochem Biophys Res Commun       Date:  2012-07-17       Impact factor: 3.575

6.  Protective effects of resveratrol on osteoporosis via activation of the SIRT1-NF-κB signaling pathway in rats.

Authors:  Xiaowei Wang; Liaobin Chen; Wei Peng
Journal:  Exp Ther Med       Date:  2017-09-20       Impact factor: 2.447

7.  Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.

Authors:  Mizuho Kittaka; Tetsuya Yoshimoto; Collin Schlosser; Robert Rottapel; Mikihito Kajiya; Hidemi Kurihara; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2019-10-24       Impact factor: 6.741

8.  Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation.

Authors:  Gabriel R Linares; Robert Brommage; David R Powell; Weirong Xing; Shin-Tai Chen; Fatima Z Alshbool; K-H William Lau; Jon E Wergedal; Subburaman Mohan
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

9.  Role of osteoclasts in oral homeostasis and jawbone diseases.

Authors:  Maiko Omi; Yuji Mishina
Journal:  Oral Sci Int       Date:  2020-07-21

10.  The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Authors:  Erola Ainsua-Enrich; Eva Serrano-Candelas; Damiana Álvarez-Errico; César Picado; Joan Sayós; Juan Rivera; Margarita Martín
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.